Siemens Healthineers Advances Medical Technology with Breakthroughs and Strategic Initiatives in 2024

Siemens Healthineers has been active with numerous initiatives and advancements. Their Neurofilament Light Chain Blood Test being first-of-its-kind for multiple sclerosis achieves CE mark, which was created in collaboration with Novartis, which aims to identify MS-related neuronal injury. Siemen’s two-year partnership with World Stroke Organization aims to enhance acute stroke workforce and improve treatment worldwide. With the new launch of Trinion next-generation biograph, siemens debuts in high performance PET/CT scanner. The scanner’s single platform supports seamless PET, CT and post-processing workflow, incorporating application for oncology, theranostics cardiovascular imaging, and neurology including Alzheimer’s disease. Siemens also introduced its new AI-powered cardiology application and a 4D transesophageal transducer for Acuson Sequoia ultrasound system.  With a heavy investment of 250m euros in a new facility in North Oxfordshire to design and manufacture superconducting magnets for MRI scans, siemens aims to focus on technology development. 

Siemens Healthineers is on track to meet fiscal year 2024 targets after second quarter as they reported a book-to-bill ratio of 1.08 and a comparable revenue growth of 3.0% (11.2% excluding COVID-19 tests). Imaging grew by 2.6% with a 20.2% EBIT margin, Diagnostics by 3.7% with a 4.1% margin, and Advanced Therapies by 8.0% with a 16.2% margin. Varian's revenue slightly declined by 2.1%, but its EBIT margin improved to 16.4%. The overall adjusted EBIT margin was 15.1%, and earnings per share were €0.55. The fiscal year outlook predicts 4.5%-6.5% revenue growth and earnings of €2.10-€2.30 per share.

Siemens announces Elisabeth Staudinger as a managing board member until September 2029. At the annual shareholder’s meeting, Siemens Healthineers AG shareholders re-elected the supervisory board members and approved a dividend of €0.95 per share for fiscal year 2023. The Siemens Healthineers AG shareholders voted on the composition of the new, co-determined supervisory board, which will have 20 members. The new structure aims to align with DAX standards, transferring over 17,000 employees to Siemens Healthineers AG.

Focusing on the development side, Siemens Healthineers integrates Hemostasis product offering in United States and Europe. This initiative will allow healthcare providers easier access to leading hemostasis testing solutions crucial for identifying and monitoring bleeding and clotting disorders.  Siemens Healthineers also developed an automated, self-driving C-arm system intraoperative imaging in surgery which will allow precise movements and easy positioning in tight spaces which can be remotely controlled by surgeons. The launch of Cinematic reality app for Apply Vision Pro enables users to interact with realistic, three-dimensional rendering of human anatomy directly on their devices. Clearance for TrueBeam and Edge Radiotherapy system featuring HyperSight Imaging solution has contributed in strategic growth of Siemens Healthineers. Siemens Healthineers started off their year with partnerships to catalyze advancements in cancer care through Varian and Nova Scotia Health.